A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients

Completed · Phase 3

Conditions studied: Hypertension

In brief

To evaluate the blood pressure lowering effect and safety of the triple combination aliskiren / valsartan / HCTZ (300/320/25 mg) in patients with essential hypertension not adequately responsive to HCTZ 25 mg

Key facts

Study ID

NCT00219193

Run by

Novartis

People needed

641

Starts

2005-10-01

Expected to finish

2007-01-01

Last updated by the study team

2017-02-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with essential hypertension
• Patients who are eligible and able to participate in the study

You may not qualify if…

• Severe hypertension
• History or evidence of a secondary form of hypertension
• Other protocol-defined exclusion criteria may apply.

Where it is running

• Novartis Pharmaceuticals — East Hanover, New Jersey, United States
• Study site — Investigative Centers, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.